HOME EDITORIAL BOARD CONTACT US SUBSCRIPTION AUTHORS INDEX AUTHORS INSTRUCTIONS SUPPLEMENTARY DATA




   
 VOLUME 15 - NUMBER 1
/ January - March 2013

 
Earlier Antiretroviral Therapy in HIV As Soon As Possible
Pablo Labarga and Francisco Blanco |Full Article in PDF|
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
 
Abstract

Two recent reports in The New England Journal of Medicine have concluded that the best way to preserve the immune system, as assessed by measuring CD4+ T-cells, is to begin antiretroviral therapy as soon as possible after HIV diagnosis. In the SPARTAC trial (Filder, et al. N Engl J Med. 2013;368:207-17), the authors investigated the effect of a short course of antiretroviral therapy on the subsequent CD4+ T-cell decline in 366 adults with primary HIV infection. Patients were randomized to 12 or 48 weeks of therapy. In both arms, antiretrovirals were initiated within six months following HIV seroconversion. After an average follow-up of four years, only the group treated during 48 weeks experienced a significant benefit, with a reduction in the hazard ratio for the primary endpoint, which was the achievement of a CD4 count > 350 cells/μl.

 
Date: 15/09/2014
ISSN: 1698-6997

 

unsubscribe 

LOGIN 
Not a member?
REGISTER 

Editor's access. 

PERMANYER PUBLICATIONS
Mallorca, 310
08037 Barcelona - Spain
Phone: +34 93 207 59 20
Fax: +34 93 457 66 42
www.permanyer.com
LINKS:
Hepatology Reviews
Hepatology Reviews
 
Cancer & Chemotherapy Reviews
Cancer & Chemotherapy
Reviews
 
trends in transplantation
Trends in Transplantation


© 2014 Permanyer Publications
Made & Powered by IMMA PUIG
Mallorca, 310 - 08037 Barcelona, Spain. Tel.: +34 93 207 59 20 - Fax: +34 93 457 66 42